Compare Etsy Inc (ETSY) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Moderna, Inc. — how do they compare? Etsy Inc trades at $76.79 (market cap $6.90B), while Moderna, Inc. trades at $224.78 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 11.4× Etsy Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Etsy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Moderna, Inc. for 59 Days on average.
| ETSY | MRNA | |
|---|---|---|
Market Cap | $6.90B | $78.65B |
Volume | 2,923,867 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $203.46 |
52-Week Low | $44.05 | $22.36 |
Typical Hold Time | 67 Days | 59 Days |
Enterprise Value | $8.85B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $76.71, up 7.3% in the last 24 hours, reflecting strong momentum. The stock shows bullish technical signals with recent earnings beats and a consensus analyst price target of $85.94. Revenue grew to $2.88B in 2025, though net income margin declined to 5.65%. Recent news highlights AI integration and payment partnerships as growth catalysts.
Outlook is positive with analyst support and strategic initiatives, but risks include high debt, margin pressure, and competitive threats. The stock offers upside to the price target but requires monitoring of execution and macroeconomic factors.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
